I'm going to continue with Ms. Boyd on patents.
I'm certain that you came across an article written by Matthew Wallace that offers potential argument in favour of patent restoration, one being that it incentivizes innovation but it offers companies enough monopoly time to allow adequate pharmaceutical development, and the lack of monopoly time would be a hindrance to drug development. I would like you to make comment on that.
Also, are you able to think of a scenario that balances a pharmaceutical drug's ability to properly develop without rushing, and a generic drug's ability to enter the market and compete?